stockrow
Monday 9 November 2026
Export ARTV’s income statement to Excel — free account
Artiva Biotherapeutics, Inc.
ARTVArtiva Biotherapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $251,000.00, down 99.3% from fiscal 2023.
- EPS
- +27.6%
- Free cash flow
- +13.6%
Quarter to June 2026, against a year earlier
4.15
0.02
+0.48%
Follow ARTV
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | 33 | 0 | — | — | (99.3%) | — | — | — | — | |
| Gross margin, % | — | — | — | — | — | — | — | 100.00 | 100.00 | — | — | 0.0 pt | ||||||
| EBT | — | — | — | — | — | — | — | (29) | (65) | (84) | (91) | +71.1% | ||||||
| EBT margin, % | — | — | — | — | — | — | — | (85.54) | (26,045.02) | 0.00 | 0.00 | +85.5 pt | ||||||
| Net income | — | — | — | — | — | — | — | (29) | (65) | (84) | (91) | +70.9% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | 41.72 | 0.02 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | — | — | — | — | (35.78) | (5.81) | (3.43) | (3.30) | (69.0%) | ||||||
| Cash flow | — | — | — | — | — | — | — | (59.09) | (4.89) | (3.14) | (1.91) | (76.9%) | ||||||
| Capex | — | — | — | — | — | — | — | (4.06) | (0.06) | (0.11) | (0.04) | (83.9%) | ||||||
| Free cash flow | — | — | — | — | — | — | — | (63.15) | (4.94) | (3.25) | (1.95) | (77.3%) | ||||||
| Book value | — | — | — | — | — | — | — | (201.84) | 16.58 | 4.50 | 8.82 | n/m | ||||||
| Shares, m | — | — | — | — | — | — | — | 1 | 11 | 24 | 28 | +451.8% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | 0.00 | 0.00 | — | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | — | — | — | 0.00 | 0.00 | — | 0.00 | 0.0 | ||||||
| P/B | — | — | — | — | — | — | — | 0.00 | 1.32 | — | 0.47 | 0.7 | ||||||
| EV/Sales | — | — | — | — | — | — | — | 0.00 | 0.00 | — | 0.00 | 0.0 | ||||||
| EV/FCF | — | — | — | — | — | — | — | 0.71 | (1.11) | — | 2.42 | (0.2) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | (47) | (55) | (77) | (75) | +27.2% | |||||
| Capex | — | — | — | — | — | — | — | (3) | (1) | (3) | (2) | (10.9%) | ||||||
| Free cash flow | — | — | — | — | — | — | — | (51) | (56) | (79) | (77) | +25.1% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | 68 | 176 | 100 | 338 | +21.4% | |||||
| Net debt | — | — | — | — | — | — | — | (77) | (185) | (108) | (349) | +18.5% | ||||||
| Shareholders’ equity | — | — | — | — | — | — | — | (162) | 187 | 110 | 348 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | 0.00 | (41.55) | (49.26) | (33.76) | (49.3) pt | |||||
| ROIC | — | — | — | — | — | — | — | 0.00 | (3,345.37) | (2,860.92) | 0.00 | (2,860.9) pt | ||||||
| ROE | — | — | — | — | — | — | — | 0.00 | (530.93) | (56.55) | (36.58) | (56.5) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | 81 | 89 | 104 | — | +13.3% | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | 0.41 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2024 · latest quarter Mar 2024 · fundamentals updated 26 Oct 2026
Artiva Biotherapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| SLGL Sol-Gel Technologies Ltd. | $206.3M | — (loss-making) | — (loss-making) | −96.58% (below 0%: shrinking) | n/m | −8.76% (below 0%: shrinking) | 100.00% | (704.23%) | Compare |
| RNAC Cartesian Therapeutics, Inc. | $205.1M | — (loss-making) | — (loss-making) | −92.91% (below 0%: shrinking) | −7.84% (below 0%: shrinking) | −6.15% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| DRUG Bright Minds Biosciences Inc. | $204.2M | — (loss-making) | — | — | n/m | −124.63% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| PLX Protalix BioTherapeutics, Inc. | $202.2M | 10.5× | 10.6× | +27.07% (above 0%: growing) | +2,280.95% (above 0%: growing) | −94.09% (below 0%: shrinking) | 60.99% | 23.48% | Compare |
| PALI Palisade Bio, Inc. | $202.2M | 1.8× | — (loss-making) | +19,900.00% (above 0%: growing) | n/m | −318.44% (below 0%: shrinking) | 100.00% | (2,339.60%) | Compare |
| ARTV Artiva Biotherapeutics, Inc. | $201.9M | — (loss-making) | — (loss-making) | — | n/m | +13.60% (above 0%: growing) | 100.00% | 0.00% | |
| IKT Inhibikase Therapeutics, Inc. | $200.9M | — (loss-making) | — (loss-making) | −100.00% (below 0%: shrinking) | n/m | −123.23% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ELDN Eledon Pharmaceuticals, Inc. | $199.9M | — (loss-making) | — | — | n/m | −28.02% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| IFRX InflaRx N.V. | $199.7M | — (loss-making) | — (loss-making) | −128.93% (below 0%: shrinking) | n/m | +59.76% (above 0%: growing) | 14,029.95% | 0.00% | Compare |
| Median of peers | $202.2M | — | — | −94.74% | — | −61.05% | 80.50% | 0.00% |
Pay and ownership Proxy statement filed 3 August 2026
Ownership
Directors and executive officers, together
1.80%
Entities affiliated with RA Capital Healthcare Fund, L.P.
36.40%
Entities affiliated with GC Corp.
12.30%
Entities affiliated with Viking Global Investors LP
5.30%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement